ServiceTitan options flow points to $50 as the next key level for TTAN

According to Investing.com, options activity on TTAN is flashing a pronounced warning sign. Put volume has reached levels not seen since June 10, 2025, and the vast majority of notable new positions are concentrated between $50 and $55, suggesting that market participants are not dismissing the possibility of a further 10–11% decline in a stock that has already fallen sharply. The upward move in skew reinforces this narrative: protective downside options are becoming increasingly costly as time passes.

Measuring the Damage

ServiceTitan Inc (TTAN) shares were trading at $56.01, down 31.34%, as of 10:21 a.m. EDT on September 9. Total options volume reached 11,302 contracts, with a put/call ratio of approximately 1.11. Three-month implied volatility stood at 67.48%, an increase of 2.43 percentage points.

Insights from the Strike Map

The four most heavily traded contracts together suggest a nuanced picture:

The most instructive option is the September 18 put struck at $50. Its prior open interest was a mere 7 contracts, but volume surged to 589. This does not appear to be protection on an existing position; rather, it looks like a straight directional wager that TTAN will trade below $50 within nine days.

The Magnetic Pull of $50

Three distinct contracts—the September $55 put, the September $50 put, and the October $50 put—cluster around the $45–$55 band. With the underlying at $56.01, the $55 put is effectively at-the-money. Rather than awaiting a rebound, institutional players are spending now to hedge at current levels. The recurrence of the $50 strike across both September and October indicates the market views it either as realistic technical support or as the likely next downside target.

Skew Reflects Rising Anxiety

The 90/110 skew climbed 1.36 percentage points to 4.55, which the options market regards as its strongest indicator: out-of-the-money puts are becoming increasingly expensive compared with calls. In simpler terms, the price of hedging against additional losses is escalating more rapidly than the cost of wagering on an upturn. The volatility surface is therefore pricing in asymmetric downside risk, rather than a balanced, two-sided market.

A Rare Bullish Bet

The September 18 call at $70—with 514 contracts traded and open interest of 51—offers the opposite view. Priced roughly 25% above the current share price with only nine days until expiry, it represents either a bold contrarian bet on a rebound or, more plausibly, call-writing intended to offset the cost of acquiring puts, a familiar collar or spread tactic. Given the modest prior open interest, this appears to be new positioning in any interpretation.

Catalysts Behind the Slide

The rout builds on a series of disappointments from second-quarter fiscal 2027 earnings. Gross transaction value growth slowed by roughly 200 basis points to 17%. Chief Revenue Officer Ross Biestman unexpectedly stepped back after almost ten years with the company. Management guided third-quarter revenue to $285–287 million, a sequential decrease from the $292.8 million reported in Q2. In addition, a strategic AI initiative called “Max” is expected to create $4–5 million in near-term revenue headwinds. Analysts responded with sharp price-target cuts—Baird moved to $85 and Canaccord to $90—although both kept Buy ratings. Read more.

Weighing the Bull and Bear Cases

From a bearish perspective, the options flow, widening skew, and build-up of near-the-money puts indicate traders bracing for a drop to $50 or lower. The departure of the CRO during an AI-driven transformation represents a leadership uncertainty that investors have yet to fully factor into the stock.

On the bullish side, Needham and Wells Fargo reaffirmed Buy ratings, net dollar retention stays above 110%, and adoption of Max doubled quarter over quarter to more than 700 customers. The activity in the $70 call suggests some participants consider the sell-off excessive. Read more.

This article was produced with AI assistance and underwent editorial review. Additional details are available in our Terms & Conditions.